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administration of WAS gene–corrected autologous
hematopoietic stem cells has been demonstrated as a feasible
alternative therapeutic approach.
Objective: Because B-cell homeostasis is perturbed in patients
with WAS and restoration of immune competence is one of the
main therapeutic goals, we have evaluated reconstitution of the
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692Methods: We evaluated B-cell counts, B-cell subset distribution, B
cell–activating factor and immunoglobulin levels, and
autoantibodyproduction before and after gene therapy (GT).WAS
gene transfer in B cells was assessed by measuring vector copy
numbers and expression of Wiskott-Aldrich syndrome protein.
Results: After lentiviral vector-mediated GT, the number of
transducedB cells progressively increased in the peripheral blood
of all patients. Lentiviral vector-transduced progenitor cells were
able to repopulate the B-cell compartment with a normal
distribution of B-cell subsets both in bone marrow and the
periphery, showing a WAS protein expression profile similar to
that of healthy donors. In addition, after GT, we observed a
normalized frequency of autoimmune-associated
CD191CD212CD352 and CD21low B cells and a reduction in B
cell–activating factor levels. Immunoglobulin serum levels and
autoantibody production improved in all treated patients.
Conclusions: We provide evidence that lentiviral vector-
mediated GT induces transgene expression in the B-cell
compartment, resulting in ameliorated B-cell development and
functionality and contributing to immunologic improvement in
patients with WAS. (J Allergy Clin Immunol 2015;136:692-702.)
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Wiskott-Aldrich syndrome (WAS; OMIM 301000) is a
complex and severe X-linked primary immunodeficiency
characterized by both cellular and humoral immunodeficiency,
microthrombocytopenia, eczema, and increased risk of
autoimmunity and lymphomas.1,2 The gene responsible for
WAS encodes a 502-amino-acid protein (Wiskott-Aldrich
syndrome protein [WASp]) that is a key regulator of actin poly-
merization.3 WASp is specifically expressed in hematopoietic
cells4 and also exerts important signaling activities independent
of cytoskeletal rearrangements.5-7 The life expectancy of patients
with WAS is severely reduced, unless they are successfully cured
by bone marrow (BM) transplantation.8 However, a significant
fraction of transplanted patients lacks a suitable HLA-matched
donor, and patients with a lower degree of chimerism, both in
the lymphoid and myeloid compartments, show an incomplete
reconstitution of lymphocyte counts and a high incidence of
autoimmunity.8,9 For these reasons, administration of WAS
gene–corrected autologous hematopoietic stem cells (HSCs)
could represent a valid alternative therapeutic approach, as
demonstrated for other primary immunodeficiencies.10
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subjects and Was2/2 mice have evaluated the feasibility and
efficacy of WAS gene therapy (GT) by means of both retroviral
and lentiviral vectors, providing the basis for the clinical applica-
tion of GT for WAS. The first clinical GT trial for WAS based on
gammaretroviral vector-mediated gene transfer, showed
sustained expression of WASp in HSCs, lymphoid cells, myeloid
cells, and platelets after GT, resulting in a considerable clinical
benefit to the patient.11 However, the occurrence of leukemias
in 7 of 10 treated patients12 has raised concerns about the use of
non–self-inactivating retroviral vectors.
We developed a GT approach based on a lentiviral vector
encoding human WASp cDNA under the control of the human
WAS endogenous promoter.13 The lentiviral GT protocol is
characterized by a reduced-intensity conditioning coupled with
depletion of B cells by anti-CD20 antibody administration before
the infusion of transduced HSCs. Our initial results in 3 patients
showed that lentiviral vector-mediated GT was feasible and led
to successful correction of HSCs, resulting in reconstitution of
WASp expression in all hematopoietic cell lineages.14
Because of the high risk of infections and autoimmune
complications, correction of immune cell functions remains the
main goal of WAS GT. Both GT trials have described an
immunologic improvement about 2 years after treatment in terms
of lymphocyte counts, in vitro T-cell functionality, use of T-cell
receptor Vb repertoire, natural killer cell immunologic synapse
formation, and cytotoxic activity.11,14 Several studies on HSC
transplantation outcomes demonstrated that successful immune
reconstitution and protection from infections require
development of humoral immune competence mediated by B
lymphocytes.15 The B-cell compartment needs to be carefully
investigated in the context of GT treatment. Indeed, WAS is
characterized by impaired humoral immunity, with skewed
immunoglobulin production and defects in polysaccharide
antigen response,2,16 indicating intrinsic abnormalities of B-cell
function. Very recently, B-cell perturbation has been described
to contribute to immunodeficiency and autoimmunity in patients
with WAS.17,18
Thus we evaluated the effects of lentiviral vector-based GT on
B-cell homeostasis and distribution, both in the BM and
peripheral blood (PB) of patients with WAS until 36 months
after treatment. To this end, we followed reconstitution of the
B-cell compartment in terms of B-cell counts, B-cell subset
distribution, plasma B cell–activating factor (BAFF) and
immunoglobulin levels, and autoantibody production in 4 patients
enrolled in the lentiviral vector-mediated GT clinical trial.METHODS
Patients, treatment, and follow-up
Clinical classification and molecular analysis are described in Table E1 in
this article’s Online Repository at www.jacionline.org. The clinical protocol
(ClinicalTrials.gov, no. NCT01515462) and criteria of eligibility for the study
have been previously described.14 Human samples were obtained after
obtaining informed consent according to the Helsinki Declaration with
approval of local medical ethics committees (TIGET02). Some of the samples
used as controls have been previously reported.18
Four male patients (age range, 1.1-5.9 years) affected by WAS were
enrolled for the lentiviral vector-mediated GT and identified as Pt1, Pt2, Pt3,
and Pt4. The clinical features of the first 3 patients have been previously
described.14 Before the treatment, they showed severe clinical conditions,
with a Zhu clinical score of 3 to 5 (see Table E1). At the time of treatment,
Pt4 was 2.4 years old, with a clinical history of neonatal sepsis; chronic cyto-
megalovirus infection with frequent reactivations; lymphadenopathies;
bleeding manifestations at the skin, gastrointestinal, and brain level; food
polyallergy with anaphylaxis; and mild eczema. The patient was given a
Zhu score of 5 because of severe refractory thrombocytopenia and the pres-
ence of circulating autoantibodies.19 All diagnoses were confirmed by genetic
analysis and evaluation of WASp expression with flow cytometry (see Table
E1). These patients, lacking an HLA-identical sibling donor and matched un-
related donor, underwent GT at a median age of 2.75 years and received a
reduced-conditioning regimen protocol preceded by anti-CD20 mAb admin-
istration.14 CD341 cells isolated from BM in all patients and also from mobi-
lized PB in Pt114 were transduced ex vivo with lentiviral w1.6W vector and
reinfused into patients at a similar dose (see transduction efficiency and vector
copy numbers [VCNs] in Table E1). Pt4, aswell as other patients, did not expe-
rience mucositis or other chemotherapy-related toxicity. Autoimmune throm-
bocytopenia persisted in the early follow-up phase in Pt4, and this patient was
treatedwith a high intravenous immunoglobulin (IVIg) dose, anti-CD20mAb,
steroids, and TPO agonists (romiplostim and eltrombopag). Autoantibody
levels against platelets became negative 5.1 months after GT, and the patient
reached platelet transfusion independence 9 months after GT, with absence of
severe bleedingmanifestations thereafter. Amultilineage expression ofWASp
was observed in Pt4 after GT, persisting up to the latest time point analyzed
(see Fig E1, A, in this article’s Online Repository at www.jacionline.org).
Flow cytometric analysis of B-cell subsets and B-cell
purification
The composition of the B-cell compartment was analyzed, as previously
described.18 Briefly, the late stages of B-cell differentiation were analyzed by
means of flow cytometric immunophenotyping with the following mAbs:
CD34-phycoerythrin (8G12; BD, San Jose, Calif), CD19-PeCy7 (SJ25C1,
BD), CD10–fluorescein isothiocyanate (MEM-78; Caltag, Burlingame, Calif),
and CD20-phycoerythrin-Texas Red/energy coupled dye (B9E9; Immunotech,
Glendale, Calif). B-cell subsets present in PB were characterized by using the
following mAbs: CD19-PeCy7 (SJ25C1, BD), CD27-allophycocyanin
(M-T271, BD) CD24-PB (SN3; Exbio, Praha, Czech Republic), CD21-
allophycocyanin (B-ly4, BD), CD38-PerCP-Cy5.5 (HIT2, BD), and CD35-
phycoerythrin (E11,BD). For intracytoplasmicdetectionof humanWASp, cells
were fixed and permeabilized with a Cytofix/Cytoperm kit (BD PharMingen).
The anti-WASp antibody 503 (a kind gift from Professors H. D. Ochs, Seattle,
Wash, and L. D. Notarangelo, Boston, Mass) was used, followed by staining
with secondaryAlexa Fluor 488– or 647–conjugated goat anti-rabbit antibodies
(Invitrogen, Carlsbad, Calif). Samples were acquired on a FACSCanto cytom-
eter and analyzedwith FlowJo Software (TreeStar, Ashland, Ore). CD191 cells
were purified frommononuclear cells derived from PB or BMbymeans of pos-
itive selection with immunomagnetic beads, according to the manufacturer’s
procedures (Miltenyi Biotec, Bergisch Gladbach, Germany).
Chemotaxis assay
The invitro chemotaxis assaywas performedwith 5mm/Lpore-sizeTranswell
inserts (Costar Corporation, Corning, NY) in 24-well plates, as previously
described.18 Briefly, CD201 cells were purified from PBMCs of patients with
TABLE I. Absolute B-cell counts in the blood of patients with WAS before and after GT
Pt1 Pt2 Pt3 Pt4
Before GT 136 mo Before GT 130 mo Before GT 130 mo Before GT 124 mo
CD19 (109/L) 0.125* (0.2-1.6) 0.333 (0.2-1.6) 0.617* (0.6-3.1) 0.257 (0.2-2.1) 0.742* (0.6-2.7) 1.895 (0.2-2.1) 0.333 (0.2-2.1) 0.240 (0.2-2.1)
Absolute counts are shown before GT and at the last follow-up after GT for all patients. Reference values for the 5th and 95th percentiles of the respective age-matched HDs were
reported by Comans-Bitter et al26 and are indicated in parentheses. Values out of the normal range are shown in boldface.
*Values previously published.14
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(Miltenyi Biotec) and left overnight at 378C in culture medium. Fifty thousand
CD201 cellswere seeded in the upper chamber. In the bottomwellwe placed cul-
ture medium supplemented with 250 ng/mL recombinant human stromal cell–
derived factor 1a (SDF-1a; CXCL12; PeproTech, Rocky Hill, NJ) or medium
alone and incubated at 378C for 3 hours. Cells migrated into the lower chamber
were counted for viable cells and stained with anti-CD19, anti-CD24, anti-
CD38, and anti-CD27 antibodies (BDBiosciences) for phenotypic analysis byus-
ing fluorescence-activated cell sorting. Migration frequency was estimated as the
percentage of migrated cells over the input cell number.
VCN
The number of lentiviral vector copies integrated per genomewas evaluated
by using quantitative PCR, as previously described.20 Results of integrated
vector copies were normalized for the number of evaluated genomes. All
the reactions were performed according to the manufacturer’s instructions
and analyzed with an ABI PRISM 7900 sequence detection system (Applied
Biosystems, Foster City, Calif).
ELISA
BAFF levels were measured in duplicate in plasma samples from patients
with WAS and HDs by using a Quantikine Human BAFF/BLyS/TNFSF13B
Immunoassay kit (R&D Systems, Minneapolis, Minn). The assay was
performed according to the manufacturer’s instructions, and OD values
were evaluated at 450 nm.
Evaluation of immunoglobulin levels and presence
of autoantibodies
Immunoglobulin levels and presence of autoantibodies were determined by
Laboraf Diagnostics and Research (San Raffaele Hospital, Milan, Italy),
according to internal standard procedures. Antibodies against platelets were
detected by using a commercially available method, the solid phase red cell
adherence test (SPRCA test, P-Capture Ready Screen; Immucor, Norcross, Ga),
whichwas designed for laboratory detection of IgG anti-platelet antibodies.21-23
Plasma samples isolated from all patients withWAS before and 2 years after
GT were also screened for the presence of autoantibodies by using an
autoantigen proteomic microarray comprising 123 different antigens.
Autoantigen microarrays were manufactured, hybridized, and scanned by the
Microarray Core Facility at the University of Texas Southwestern Medical
Center (Dallas, Tex)24 in a blindmanner.Aheatmapwas generated based on the
normalized fluorescent intensity of autoantibodies and on a color scale range
between 12 and 22 SDs. Values were mean centered, and antigens with a
signal-to-noise ratio of less than 3 were considered undetectable and removed
in both pre-GT and post-GT samples, thus reducing the number of antigens
from 123 to 93. Differences related to each antigen between pre- and post-GT
samples were evaluated by using the paired t test, and a global test P value
was computed by using the global test R package to evaluate differences related
to the whole antigen profile between pre- and post-GT samples.Statistical analysis
All results are expressed asmeans6 SDs, if not stated otherwise. Statistical
significance was assessed by using 2-tailed Mann-Whitney tests for compar-
isons between patients and HDs or paired t tests for comparisons before and
after treatment. P values of less than .05 were considered significant.RESULTS
Treatment and follow-up
After treatment with lentiviral vector-mediated GT, all patients
showed a stable and multilineage engraftment of transduced
HSCs, with expression of WASp progressively increasing and
persisting in the different hematopoietic cell lineages. No adverse
events related to the treatment were observed after GT, and all
patients were alive and clinically well at the time of this study
(Aiuti et al14 and unpublished results). Frequency and severity of
infections and bleeding were reduced after the first year of follow-
up. All patients became independent from platelet transfusions,
with platelet counts progressively increasing over time, although
not reaching normal levels. Eczema improved in all 4 patients,
and no clinical manifestations of autoimmunity were observed
after the first year of follow-up. All patients discontinued
anti-infectious prophylaxis, and 2 of 4 (Pt1 and Pt3) stopped
IVIg supplementation as well. After IVIg suspension, the 2
patients received regular vaccinations, and both showed a
protective response to T cell–dependent antigens. Pt1 produced
specific IgM after 2 doses of unconjugated vaccine (Pneumovax;
Merck & Co, Whitehouse Station, NJ). Because protective
antibody levels were not reached, the patient received 2 doses
of conjugated pneumococcal vaccine (Prevnar 13; Wyeth, Dallas,
Tex) and was able to mount a protective response.Reconstitution and gene correction of B
lymphocytes
We have previously demonstrated the efficacy of lentiviral
w1.6W vector in restoring B-cell defects in a WAS mouse
model.25 On the basis of this evidence, we evaluated the effect
of GT on the B-cell compartment in patients with WAS. To this
end, we followed the reconstitution, transduction levels, and
expression of WASp in B lymphocytes of 4 patients with WAS
treated with GT. Before treatment, only Pt1 presented with few
CD191 B cells in PB, whereas B-cell counts were in the normal
range in the remaining patients (Aiuti et al14 and Table I).14,26
During the first months after GT treatment, we observed a low
number of B cells (unpublished results), as expected because of
the combined effect of conditioning regimen and anti-CD20
mAb administration, which progressively increased, reaching
the range of normality (Table I). All treated patients expressed
WASp in CD191 cells (Figs 1 and 2),14 demonstrating that newly
generated B cells arising from transduced progenitor cells stably
expressed the transgene. In PB the frequency of CD191 cells
expressing WASp was significantly increased 6 months after
GTand remained stable over time at the last follow-up (Fig 1, A).
When feasible, we analyzed WASp expression in BM-isolated
B cells in parallel to PB analysis (Fig 1, B). Higher frequencies of
WASp-positive B cells were detected in PB compared with BM in
all patients (Fig 1). Transduction levels were evaluated as VCNs
in B cells isolated from PB and BM (see Fig E1, B and C).
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progressively increased in PB of all patients from the first months
after GT. Furthermore, the higher WASp expression level in PB is
in line with the higher VCN found in PB compared with BM,
indicating a selective advantage of gene-corrected B cells in the
periphery.Kinetics of B-cell reconstitution in BM and PB after
GT
We have previously demonstrated that WASp deficiency
perturbs B-cell development, starting in the BM, where we
described an altered distribution of B-cell precursor subsets.18
Thus we evaluated whether GT treatment could restore a
normal distribution pattern in BM. As expected, patients
showed a significantly high proportion of small pre-B-II cells
(CD342CD191CD10intCD202) and a low proportion of
immature B cells (CD342CD191CD10intCD201) before GT,
which reverted to normal in all patients 1 year after treatment
(Fig 3, A).
Next, we evaluated PBB-cell subpopulation distribution before
and after treatment. Before GT, transitional B-cell frequencies(CD191CD24highCD38high) were higher in Pt2 and Pt3 when
compared with HDs (Fig 3, B). Three months after treatment,
transitional B cells represented the first subset detected at a
high proportion in PB and then progressively decreased to propor-
tions lower than pre-GT values (at 30 months after GT, P5 .049),
reaching normal values 24 months after GT (P5 .7566; Fig 3, B).
In parallel, the proportion of mature naive B cells
(CD191CD24dimCD38dim) increased over time to reach values
comparable with those observed in HDs (P 5 .3489; Fig 3, C).
With regard to mature B-cell subsets, we observed that Pt1, Pt2,
and Pt4 had normal percentages of memory B cells
(CD191CD271) before and after GT (Fig 3, D). Pt3 displayed
a severe reduction in memory B-cell frequency before GT
(1.5% WAS before GT vs 4.7% to 19.2%, minimum and
maximum values of HDs at <3 years, respectively), which
increased up to values within the HD range 30 months after
treatment (7.38% Pt3 vs 7.0% to 24.4%, minimum and maximum
values of HDs at 3-12 years, respectively; Fig 3, D). Analysis of
switched memory B cells in treated patients showed a trend
similar to that of total memory B cells 2 years after GT
(unpublished results). Plasmablasts (CD191CD242CD38high)
were in the normal range of values before and after GT, with
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proportion before GT that normalized after therapy (Fig 3, E).
To evaluate whether the normalization of B-cell subset
distribution in the BM and PB in treated patients was associated
with a qualitative improvement in B-cell function, we tested their
in vitro chemotactic response to SDF-1a, which we previously
described as defective in patients with WAS.18 We confirmed
that WASp-deficient B cells isolated from 2 patients (Pt2 andPt3) before GT were less responsive to SDF-1a and observed
that they had a normal migratory ability after GT (Fig 3, F-H).
Indeed, the percentages of in vitro–migrated transitional (Fig 3,
G) and mature naive (Fig 3, H) B cells after GT were higher
than those before GT and comparable with those of HDs.
Because the absence of WASp perturbs B-cell subset
distribution in human subjects17,18,27 and mice,28,29 we compared
differential WASp expression during B-cell maturation in HDs
J ALLERGY CLIN IMMUNOL
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fluorescence intensity levels of WASp in different B-cell subsets
in the blood of pediatric HDs, we detected a differential pattern of
WASp expression among peripheral B-cell subsets. WASp is
expressed at significantly higher levels in memory B cells
compared with levels in transitional and mature naive B cells
(Fig 2, A), suggesting that WASp expression is modulated in the
different B-cell populations. In patients undergoing GT, we
noticed the same pattern of WASp expression in different B-cell
subpopulations, in particular in memory B cells (Fig 2, B). These
data strongly suggest that the lentiviral vector-transduced CD341
cells were able to repopulate the B-cell compartment with a
normal distribution of B-cell subsets both in BM and the
periphery, presenting a WASp expression profile similar to that
of HDs.Correction of immunophenotypic perturbation of B
cells from patients with WAS after GT
To further characterize the composition of the peripheral B-cell
compartment, we analyzed the expression of 2 complement
receptors, CD35 and CD21, involved in maintenance of
self-tolerance30,31 and less expressed by B cells from patients
with WAS.18,27
When we analyzed the expression of CD21 and CD35 before
GT, we found a lower proportion of double-positive cells in all
patients compared with HDs, with the exception of Pt3 (Fig 4, A
and B). Three months after GT, an increase in the percentage of
CD191CD211CD351 B cells was already noticeable and
reached statistical significance 1 year after GT compared with
values before treatment (mean frequency of all patients 1 year
after GT is 85.8% compared with 46.6% before GT). Moreover,
the frequency of CD191CD211CD351 B cells remained stable
until the last follow-up, with levels similar to those of HDs
(Fig 4, B). Interestingly, Pt3 showed complete absence of the
CD21/CD35 double-negative population 2 years after treatment.
The B-cell compartment of patients with WAS is also
characterized by the presence of an unusual population
phenotypically identified as CD191CD212CD382 (referred to
as CD21low)18 that were enriched in autoreactive and
unresponsive B cells that could be involved in the breakdown of
B-cell tolerance.32-34 Before treatment, patients with WAS
presented with an increased frequency of CD21low B cells, which
diminished 3 months after GT, becoming nearly absent starting at
18 months after treatment (Fig 4, C and D). We also assessed
plasma BAFF levels, which are known to play a role in B-cell
homeostasis and peripheral tolerance.35,36 Higher BAFF levels
were found in all patients before GT compared with those of
age-matched HDs (P 5 .0018; Fig 4, E). GT treatment led to a
decrease in BAFF plasma levels in all treated patients, although
they still remained statistically different from HDs (.0018 vs
.015, P value of pre-GT patients and HDs vs P value of patients
with WAS 30 months after GT and HDs).In vivo B-cell function after GT
To evaluate B-cell functionality, we monitored production of
immunoglobulins and autoantibodies before and after GT. Pt114
and Pt3 have been taken off IVIg administration 10 and 20months
after treatment, respectively. Pt3 had IgG serum levels within the
normal range at the last determination point, whereas in Pt1 IgGserum levels were less than the normal range (Table II). The eval-
uation of IgG levels in Pt214 and Pt4 was not informative because
of IVIg administration. Of note, Pt2 and Pt4 experienced autoim-
mune thrombocytopenia in the first months after GTand received
high doses of IVIg and anti-CD20mAb, whichmight have slowed
down the reconstitution of the B-cell compartment and delayed
IVIg discontinuation. Before GT, patients showed variable levels
of immunoglobulin classes. Pt1 had low IgM serum levels, which
improved after treatment but remained less than normal levels.
IgE levels improved in Pt2 after treatment, although IgM and
IgA levels were still out of the range of normality. Pt3 showed
higher IgA and IgE serum levels before treatment, which
decreased after therapy. Pt4 showed lower IgM and higher IgE
levels compared with HDs but improved after GT (Table II).
Patients with WAS have a higher risk of autoimmune
manifestations,2 even after HSC transplantation, when complete
chimerism is not achieved.8 Thus we examined the production
of autoantibodies in the sera of patients with WAS undergoing
GT before and after GT (Table III). No positivity for anti–liver
kidney microsomal antibodies, anti–smooth muscle antibodies,
anti-mitochondrial antibodies, anti-DNA, perinuclear ant-
neutrophil cytoplasmic antibodies, anti-neutrophil cytoplasmic
antibodies, and direct and indirect Coombs tests was found before
and after GT. Before GT, Pt3 showed anti-platelet antibodies,
which were still present 2 years after GT, whereas anti-nuclear
antibody levels normalized after GT. In Pt4 anti-platelet
antibodies were present before treatment and disappeared at the
last follow-up.
Furthermore, to extend the analysis to a broader panel of
autoantigens, we used a high-throughput autoantigen microarray
platform that contains 123 different autoantigens. We observed a
trend toward global decreased reactivity to autoantigens in the
plasma of patients with WAS 2 years after therapy versus before
GT (global test P 5 .0693). Several antigens were significantly
downregulated (P < .05, Fig 5).DISCUSSION
In the present study we demonstrate that lentiviral vector-
transduced hematopoietic progenitor cells can differentiate into
WASp-expressing B cells, leading to normalization of B-cell
development both in BM and PB. We show the correction of
phenotypic perturbations of B cells from patients withWAS and a
decrease in plasma BAFF concentrations toward levels in
age-matched HDs. In addition, B-cell reconstitution led to
discontinuation of IVIg infusions in 2 patients (Pt1 and Pt3).
We observed that GT normalized the proportions of early
B-cell subsets, indicating that B-cell development occurs
normally in the BM after GT. An increased proportion of
immature B cells was observed in the BM of treated patients in
association with a decrease in transitional B-cell numbers in the
periphery in contrast to what has been described in untreated
patients with WAS.18 We have previously demonstrated that the
overrepresentation of transitional B cells in the PB of patients
with WAS is, at least in part, due to an early export of immature
B cells from the BM because of the inability of B cells from
patients with WAS to sense retention signals mediated by
CXCR4 and its ligand, SDF-1a.18 Thus the restoration of proper
retention signals mediated by WASp could contribute to the
normalization of immature B cells in the BM and transitional B
cells in the periphery.
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FIG 4. Normalization of phenotypic alterations of B cells from patients with WAS and BAFF levels after GT.
A and B, CD21 and CD35 expression on CD191 cells in patients with WAS before and after GT and
in HDs (n 5 16). C and D, CD21low B cells in patients with WAS before and after GT and in HDs (n 5 45).
E, BAFF levels before and after GT and in HDs (n 5 24). Asterisks above horizontal lines indicate significant
differences between patients with WAS and HDs. Asterisks without lines define differences between pre-GT
and post-GT samples. **P <_ .005 and *P < .05.
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TABLE II. Immunoglobulin levels in the sera of patients with WAS before and after GT
Pt1 Pt2 Pt3 Pt4
Before GT 136 mo Before GT 130 mo Before GT 130 mo Before GT 124 mo
IgG (g/L) 5.21 (3.4-12.4) 5.45 (6.5-16.0) 7.93* (3.4-12.4) 6.68* (3.4-12.4) 14.01* (3.4-12.4) 8.95 (3.4-12.4) 9.29* (3.4-12.4) 4.95* (3.4-12.4)
IgM (g/L) 0.11 (0.48-2.2) 0.38 (0.48-2.2) 0.77 (0.48-2.2) 0.35 (0.48-2.2) 0.59 (0.48-2.2) 0.68 (0.48-2.2) 0.28 (0.48-2.2) 0.44 (0.48-2.2)
IgA (g/L) 1.51 (0.35-2.0) 1.38 (0.45-2.5) 1.63 (0.15-1.1) 1.99 (0.18-1.6) 4.18 (0.15-1.1) 4.69 (0.18-1.6) 0.8 (0.18-1.6) 0.58 (0.18-1.6)
IgE (UI/mL) 24 (1.0-60.0) 30.8 (1.0-60.0) 184 (1.0-60.0) 55 (1.0-60.0) 314 (1.0-60.0) 97 (1.0-60.0) 180 (1.0-60.0) 117 (1.0-60.0)
Serum IgG, IgM, IgA, and IgE levels before GT and at the last follow-up are shown. The corresponding interquartile ranges of age-matched HDs (Laboraf reference values) are
reported in parentheses. Values out of the normal range are shown in boldface.
*Patient receiving IVIg therapy.
TABLE III. Autoantibodies in the sera of patients with WAS before and after GT
LKM ASMA AMA Anti-DNA p-ANCA c-ANCA Direct Coombs Indirect Coombs Anti-plt ANA* *if 1 search for ENA
Pt1
Before GT 2 2 2 2 2 2 2 2 2 2 ND
11 y 2 2 2 2 2 2 ND ND 2 2 ND
12 y 2 2 2 2 2 2 2 2 ND 2 ND
Pt2
Before GT 2 2 2 2 2 2 2 2 2 2 2
11 y 2 2 2 2 2 2 2 2 2 2 2
12 y 2 2 2 2 2 2 2 2 2 2 2
Pt3
Before GT 2 2 2 2 2 2 2 2 1 11:160 2
11 y 2 2 2 2 2 2 2 2 ND 2 2
12 y 2 2 2 2 2 2 2 2 1 2 2
Pt4
Before GT 2 2 2 2 2 2 2 2 1 2 2
11 y 2 2 2 2 2 2 2 2 2 2 2
12 y 2 2 2 2 2 2 2 2 2 2 ND
2, Negativity to antigens; 1, positivity to antigens together with autoantibody titers; AMA, anti-mitochondrial antibodies; ANA, anti-nuclear antibodies; anti-plt, anti-platelet
antibodies; ASMA, anti–smooth muscle antibodies; c-ANCA, cytoplasmic anti-neutrophil cytoplasmic antibodies; ENA, anti-extractable nuclear antibodies; LKM, anti–liver kidney
microsomal antibodies; ND, not done; p-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies.
*Patient receiving IVIg therapy.
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 3
CASTIELLO ET AL 699Several studies in WAS murine models have shown that WASp
is crucial for peripheral B-cell homeostasis but could be
dispensable during early murine hematopoiesis.25,28,29,37 Our
analysis of WASp expression in B cells from patients undergoing
GT confirms the selective advantage of WASp-expressing cells in
the periphery with respect to the BM compartment. In particular,
at the peripheral level WASp is highly expressed in mature B
cells, such as memory cells and plasmablasts. These data are in
agreement with findings reporting a selective advantage of
WASp-positive mature B cells in competitive transplant settings
and heterozygous mice28,29 and further confirm the preclinical
data of lentiviral vector-mediated GT inWas2/2 mice.25 Howev-
er, similar to the retroviral vector-mediated GT trial,11 WASp-
negative cells are still present in the B-cell compartment in our
patients. This is in line with results obtained from preclinical
studies conducted in sublethally irradiated Was2/2 mice treated
with Was2/2 cells transduced with the w1.6W lentiviral vector
(the same vector used in our trial). However, even in the presence
ofmixed chimerism ofWASp-positive andWASp-negative B cells,
GT led to an improvement inB-cell function in terms of response to
T cell–independent antigens and autoantibody titers.25 In our
cohort of patients with WAS, 2 of 4 treated patients discontinued
immunoglobulin treatment, and 1 is decreasing the frequency of
infusions, suggesting that in vivo B-cell function is being restored.
Importantly, the reduced-intensity conditioning regimen
(low doses of busulfan and fludarabine) and administration ofanti-CD20 mAb, which is chosen in patients undergoing GT to
avoid conditioning-related toxicity, might affect the kinetics of
B-cell reconstitution. Indeed, observations obtained from the
outcome of HSC transplantation in a cohort of pediatric patients
with WAS indicate a better disease-free survival in patients
receiving a fullymyeloablative conditioning regimen,38 similar to
observations previously reported for B-cell reconstitution in
patients with severe combined immunodeficiencies.39 To this
end, data from ongoing GT clinical trials performed in different
centers using the same clinical vector in patients with WAS but
different conditioning regimens will be instrumental to under-
stand the relevance of conditioning in the kinetics of immune
reconstitution in autologous BM transplantation.
During B-cell development, the maintenance of the primary
B-cell pool and the fate of self-reactive B cells are largely
coordinated by B-cell receptor, BAFF, and its receptor.35,40
Before GT, increased BAFF plasma levels, which might decrease
the threshold for the survival of autoreactive B-cell clones,35 were
found in patients with WAS similar to those reported in patients
with other immunodeficiencies41 and autoimmune diseases.42-45
Thus we hypothesize that the reduced BAFF plasma levels found
in GT-treated patients, reflecting the improvement in B-cell
lymphopenia and B-cell subset distribution,41 could ultimately
result in a less favorable environment for survival of autoreactive
B cells. Consistently, we observed a significant decrease in
CD21low B-cell frequencies, which were described to be enriched
FIG 5. Decreased autoantibody production in patients with WAS after GT. IgG reactivities against 123
antigens were tested by using an autoantigen array. P values resulting from paired t tests of differential
expression between pre-GT and matched post-GT samples are shown in the left panel. Blue and green
bars refer to autoantibodies with higher expression in pre-GT and post-GT samples, respectively.
The vertical line indicates a P value of less than .05. Data are represented as a heat map (right panel),
with values mean centered and colors scaled from 22 to 12 SD. The legend shows z scores.
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CASTIELLO ET AL 701in anergic autoreactive clones32 and expanded in patients with
autoimmune diseases.32,34,46 CD21low B cells, which were
probably removed by anti-CD20 administration, might not find
favorable conditions to expand after GT treatment. However,
patients have not yet normalized BAFF levels 2 years after GT,
suggesting that full recovery of the B-cell compartment might
require more time. Of note, the slow kinetics of BAFF level
reduction were also observed in adenosine deaminase–deficient
patients after GT47 and might be associated with the use of a
reduced-intensity conditioning.48 Finally, upon GT treatment,
we observed a correction of the expression of the complement
receptors CD21 and CD35, which are involved in the capture
and presentation of opsonized antigens49 and in negative selection
of self-reactive B lymphocytes30 and represent a common trait in
patients with WAS.18,27
In conclusion, although longer follow-up is required to evaluate
full B-cell restoration, our data indicate that the lentiviral vector-
mediated GT treatment for WAS is efficacious in inducing WASp
expression in B cells, leading to a correction of phenotypic
perturbation and resulting in a robust and stable B-cell
reconstitution.
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Clinical implications: Lentiviral vector-mediatedGT treatment
for WAS restores WASp expression in B cells and corrects
phenotypic perturbations.REFERENCES
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FIG E1. WASp expression and transduction levels after GT. A, Histogram plots showing WASp expression
measured by means of cytofluorimetric analysis in different hematopoietic cells of Pt4 before and 2 years
after GT and an HD. Negative controls are shown as gray histograms. B and C, Transduction levels are
shown in the graph as VCNs per genome evaluated by means of quantitative PCR at different time points
after GT in B cells purified either from PB (Fig E1, B) or BM (Fig E1, C).
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TABLE E1. Features of patients with WAS treated with lentiviral vector-mediated GT
Pt1* Pt2* Pt3* Pt4
Zhu score 3 4 4 5
WAS mutation Exon 10
c.961C>T
(R321X)
Exon 10
c.1337_133819del
Exon 1
c.37C>T
(R13X)
Exon 1
c.91G>A
(E31K)
WASp expression <5% <5% <5% <5%
Years at treatment 5.9 1.6 1.1 2.4
Cell dose (3106/kg) 3.66 (BM) 1 5.25 (MPB) 14.1 (BM) 10.2 (BM) 10.3 (BM)
VCN 1.9-1.4 2.4 2.8 2.4
Transduction efficiency in CFC 92% (BM); 88% (MPB) 97% 100% 94%
FU at study analysis 36 mo 30 mo 30 mo 24 mo
Current clinical condition Alive and well
No eczema
No major bleeding
Off IVIg
Alive and well
No eczema
No major bleeding
Receiving IVIg
Alive and well
No eczema
No major bleeding
Off IVIg
Alive and well
No eczema
No severe infections
Receiving IVIg
c., Coding DNA; CFC, colony-forming cells; FU, follow-up; MPB, mobilized peripheral blood.
*Aiuti et al.14
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